The FDA on August 30, 2012 granted accelerated approval for AFINITORĀ® (Everolimus) for the treatment of pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. AFINITORĀ® tablets for oral suspension (AFINITORĀ® Disperz) is a product of Novartis Pharmaceuticals Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
